BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 2005 UBS Global Life Science Conference in New York City on Wednesday, September 28, 2005 at 10:00 a.m. ET.

Interested parties can access a live audio broadcast of the presentation via the investor section of the BioMarin website, www.BMRN.com. A replay will be available on the site for at least one week following the live presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), and Orapred(R) (prednisolone sodium phosphate oral solution) for inflammatory conditions. Investigational product candidates include Phenoptin(TM) (sapropterin hydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU). For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

NOTE: Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Orapred(R) is a registered trademark of Medicis Pediatrics, Inc. and is used under license.

  Contacts:

   Investors                         Media
   Joshua A. Grass                   Susan Ferris
   BioMarin Pharmaceutical Inc.      BioMarin Pharmaceutical Inc.
   415-506-6777                      415-506-6701

SOURCE: BioMarin Pharmaceutical Inc.